Capricor outlines deramiocel PDUFA date of August 22, 2026 while targeting 2,000 to 2,500 patients per year manufacturing capacity [Seeking Alpha]
Capricor Therapeutics, Inc. (CAPR)
Last capricor therapeutics, inc. earnings: 3/18 04:01 pm
Check Earnings Report
US:NASDAQ Investor Relations:
capricor.com/investors
Company Research
Source: Seeking Alpha
Linda Marbán said the “most significant development” is that “our biologics license application, or BLA, for deramiocel is currently under active review by the FDA with a PDUFA target action date of August 22, 2026,” adding that Newsletters for Every Investor Get daily, sector-specific newsletters packed with expert insights, fresh ideas, and new opportunities. Subscribe to Newsletters Sign Up Quick Insights Capricor is shifting from supporting NS Pharma to preparing for an independent launch, citing the lawsuit's aim to regain control due to unworkable pricing. The lawsuit creates legal and timing uncertainties, but management states the FDA review timeline is unaffected. Deramiocel's biologics license application is under FDA review with active information requests. HOPE-3 met efficacy endpoints, and Capricor expects near-term labeling discussions. Manufacturing planning and some launch steps depend on FDA label guidance. Capricor reported $279 million in liquidity,
Show less
Read more
Impact Snapshot
Event Time:
CAPR
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
CAPR alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
CAPR alerts
High impacting Capricor Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
CAPR
News
- Capricor Therapeutics Eyes FDA Approval Path for Duchenne Cell Therapy [Yahoo! Finance]Yahoo! Finance
- Capricor Therapeutics, Inc. (CAPR) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript [Seeking Alpha]Seeking Alpha
- Capricor Therapeutics to Present at Upcoming Investor ConferencesGlobeNewswire
- Deramiocel Outlook Strengthens Capricor Therapeutics, Inc. (CAPR) as a Small-Cap Stock to Buy [Yahoo! Finance]Yahoo! Finance
- Capricor: I Rate It A Buy After Stress-Testing The Sell Thesis [Seeking Alpha]Seeking Alpha
CAPR
Earnings
- 5/12/26 - Miss
CAPR
Analyst Actions
- 5/13/26 - HC Wainwright
CAPR
Sec Filings
- 6/8/26 - Form 8-K
- 5/28/26 - Form 4
- 5/28/26 - Form 3
- CAPR's page on the SEC website